scholarly journals Repurposing a novel parathyroid hormone analogue to treat hypoparathyroidism

2017 ◽  
Vol 175 (2) ◽  
pp. 262-271 ◽  
Author(s):  
Venkatesh Krishnan ◽  
Yanfei L Ma ◽  
Catherine Z Chen ◽  
Natasha Thorne ◽  
Heather Bullock ◽  
...  
2006 ◽  
Vol 47 (2) ◽  
pp. 214 ◽  
Author(s):  
Yumie Rhee ◽  
Weontae Lee ◽  
Eun Jin Lee ◽  
Suhyun Ma ◽  
So Young Park ◽  
...  

1987 ◽  
Vol 253 (2) ◽  
pp. E187-E192
Author(s):  
N. Horiuchi ◽  
M. Rosenblatt

The antagonist properties of a bovine parathyroid hormone analogue ([Tyr34]bPTH-(7-34] amide were quantitatively assessed in vivo in a multiparameter assay to estimate the potency of the antagonist against the major actions of PTH. The analogue inhibited PTH-stimulated urinary excretion of phosphate and adenosine 3',5'-cyclic monophosphate in vitamin D-deficient thyroparathyroidectomized rats in a dose-dependent manner. At a molar dose ratio as low as 5:1 of antagonist to PTH, partial inhibition occurred. PTH stimulates the activity of 25-hydroxyvitamin D3-1 alpha-hydroxylase in renal proximal tubules. When coinfused with PTH, this analogue completely inhibited PTH-stimulated 1 alpha-hydroxylase activity at a molar dose ratio of 25:1 of antagonist to PTH and partially inhibited the activity at a molar dose ratio of 10:1. The analogue revealed no PTH-like agonist activity for stimulation of the 1 alpha-hydroxylase. Taken together, these studies indicate that [Tyr34]bPTH-(7-34) amide is a potent antagonist of several of the parameters of PTH action in vivo and demonstrate the feasibility of designing a PTH antagonist that can interact simultaneously with all the PTH receptors responsible for the hormone's major actions in vivo.


1991 ◽  
Vol 181 (1) ◽  
pp. 481-485 ◽  
Author(s):  
Wing L. Sung ◽  
Cathy K. Luk ◽  
Diana M. Zahab ◽  
Jean R. Barbier ◽  
Marc Lafontaine ◽  
...  

Author(s):  
J.-R. Barbier ◽  
V. Ross ◽  
P. Morley ◽  
J.F. Whitfield ◽  
G.E. Willick

Sign in / Sign up

Export Citation Format

Share Document